gefitinib has been researched along with withaferin a in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (withaferin a) | Trials (withaferin a) | Recent Studies (post-2010) (withaferin a) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 590 | 22 | 454 |
| Protein | Taxonomy | gefitinib (IC50) | withaferin a (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.585 | |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | 0.047 | |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | 0.047 | |
| Transcription factor p65 | Homo sapiens (human) | 0.047 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M | 1 |
1 other study(ies) available for gefitinib and withaferin a
| Article | Year |
|---|---|
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays | 2017 |